Relay Therapeutics Partners with Elevar Therapeutics in $500M Deal for Lirafugratinib in Rare Cancer Treatment

Partnership Agreement:
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for lirafugratinib (RLY-4008), a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other FGFR2-altered solid tumors12.

Financial Terms:
The deal is worth up to $500 million, including $75 million in upfront and regulatory milestones, plus up to $425 million in potential commercial milestone payments, and tiered royalties up to the low-teens percentage12.

Development and Commercialization:
Elevar Therapeutics will assume full responsibility for all further development activities, including submission of NDAs, subsequent clinical development, and global commercialization for FGFR2-driven CCA and FGFR2-altered other solid tumors1.

Disease Background:
Cholangiocarcinoma (CCA) or bile duct cancer is a rare disease with approximately 8,000 people diagnosed in the United States each year1.

Regulatory Pathway:
The FDA recommended that the company first file an NDA for FGFR2-driven CCA, followed by a supplemental NDA for FGFR2-altered other solid tumors with data from an expanded cohort of patients1.

Sources:

1. https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-and-elevar-therapeutics-announce-exclusive/

2. https://www.fiercebiotech.com/biotech/relay-passes-baton-elevar-handing-nda-ready-rare-cancer-asset-500m